2633:TWSETaiwan High Speed Rail Corporation Analysis

Jacobson Pharma is trading at HK$1.10, barely above its technical support of HK$1.09, while the 20‑day SMA (1.138) sits well above the current price, indicating a bearish momentum. The 14‑day RSI of 38 and a bearish MACD histogram reinforce the downside bias, and the stock’s beta of –0.05 suggests it moves opposite to the market, adding to the uncertainty. Volatility is elevated at 23.7% over the past 30 days, and the max drawdown of nearly 38% highlights historical price weakness. The Fear & Greed Index is at an “Extreme Greed” level (86.7), which may signal over‑optimism in the broader market despite the stock’s own bearish signals. Fundamentally, the company trades at a trailing PE of 7.33 versus an industry average of 24.85, and its price‑to‑book is just under 1.0, suggesting a value tilt. However, revenue has contracted by 5.4% and the DCF‑derived fair value of HK$0.31 is far below the market price, implying the market may be overpaying. Dividend yield is exceptionally high at 7.73%, with a payout ratio of 59%, and operating cash flow remains positive, supporting dividend sustainability. Yet, total debt of HK$904.6 million against a debt‑to‑equity of 40% and a modest ROE of 12.8% raise concerns about financial leverage. The company’s margins are decent (gross 44%, operating 24%, profit 20%) but the lack of revenue growth limits upside. Overall, the stock appears overvalued on a DCF basis, offers a strong yield, but faces significant technical and financial headwinds.